Quantcast
Last updated on April 18, 2014 at 15:29 EDT

Latest Biosimilar Stories

2013-10-15 23:02:08

DIA will host the 8th Annual Conference on The New Clinical Research Environment in India: Implications and Opportunities Oct. 24 to 26 at the National Institute of Mental Health and Neuro Sciences’ convention center in Bangalore. BANGALORE, India (PRWEB) October 15, 2013 DIA will host the 8th Annual Conference on The New Clinical Research Environment in India: Implications and Opportunities Oct. 24 to 26 at the National Institute of Mental Health and Neuro Sciences’ convention center...

2013-10-12 23:02:01

RnRMarketResearch.com adds Latest Report on “Biological and Biosimilars Drug Market in Poland 2013” to its store. The report provides Biologic and biosimilars drug market in Poland 2013, Development forecasts for 2013-2015 is a long-awaited business information tool. Dallas, TX (PRWEB) October 12, 2013 Examine the future of biologics in the Polish pharma market. Report surveys biologic and biosimilar drugs, epidemiology and growth potential 2013- 2015. In Poland, as in many parts of...

2013-10-10 23:23:12

Therapy Class Overview: Rituximab biosimilar is the new market research report added to ReportsnReports.com store. Dallas, Texas (PRWEB) October 10, 2013 Approval of Inflectra/Remsima, the first biosimilar Monoclonal antibody (Mab) from Celltrion and Hospira in EU in 2013 is a trend setter! Inflectra is a biosimilar of Johnson & Johnson's Remicade, which is approved for RA, Crohn's disease and several other conditions and had $2 billion in sales in Europe last year. This...

2013-10-10 08:28:54

Discover key global trends in the ambiguous biosimilars market during Frost & Sullivan's complimentary webinar MOUNTAIN VIEW, Calif., Oct. 10, 2013 /PRNewswire/ -- WHEN: 1:00 p.m. EDT on Thursday, Oct. 17, 2013 LOCATION: Online, with free registration SPEAKER: Frost...

2013-10-09 08:27:19

SOUTH SAN FRANCISCO, Calif., Oct. 9, 2013 /PRNewswire/ -- Catalyst Biosciences, Inc., focused on discovering and developing novel biopharmaceutical products based on engineered human proteases, and Isu Abxis, an established biologics manufacturing and development company based in Seoul Korea, announced today the companies have formed a strategic collaboration to develop Catalyst's next-generation Factor IX development candidate FIX-NG (CB 2679d) for the prevention and treatment of...

2013-10-07 16:25:21

NEWARK, Del., Oct. 7, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO), a biotechnology company focused on commercializing its proprietary transformative recombinant platform technology for development and production of biologics using transient gene expression in unmodified green plants, today confirmed, as required by Section 610(b) of the NYSE MKT Company Guide, the receipt of an audit opinion for its year ended June 30, 2013, containing a going concern qualification. This...

2013-09-23 23:19:52

Reportbuyer.com just published a new market research report: Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors London (PRWEB) September 23, 2013 Product Description The new Competitive Intelligence Report Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors of May 2013 provides a competitor analysis of the product portfolios and development pipelines of ten major classes of therapeutic proteins and their biosimilar and...

2013-09-23 23:02:42

Healthcare regulators, innovators, researchers, regulatory professionals and stakeholders from around the world will converge in Boston for the largest annual gathering for the healthcare product regulatory profession. Rockville, MD, USA (PRWEB) September 23, 2013 Healthcare regulators, innovators, researchers, executives from pharmaceutical, biotechnology and medical device companies, and other regulatory professionals and stakeholders from around the world will gather at the Hynes...

2013-09-23 08:28:07

-To avoid frivolous brand tactics and confusion in the marketplace, company urges use of identical, non-proprietary names to promote ongoing efforts to expand access and ensure patient safety- PITTSBURGH, Sept. 23, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today expressed support for the Generic Pharmaceutical Association's (GPhA) filing of an official Citizen Petition with the Food and Drug Administration (FDA) detailing the industry's position on biosimilar naming. The petition...

2013-09-16 23:18:34

Reportbuyer.com just published a new market research report: PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022. London (PRWEB) September 16, 2013 PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet...